Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

krema

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 in 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - Živi aroa geni so bili izbrisani escherichia coli, tip 078, seva ec34195 - immunologicals za aves, Živih bakterijskih cepiv - chicken; turkeys - za aktivno imunizacijo o pitovnih piščancev in prihodnosti plasti / rejcev, da bi zmanjšali umrljivost in poškodb (perikarditis, perihepatitis, airsacculitis), ki je povezana z escherichia coli, serotip o78.

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus, živi oslabljeni, ošpice, virus, živi oslabljeni, mumps, virus, živi oslabljeni, rdečkam, virus, živi oslabljen, noric - chickenpox; rubella; measles; mumps; immunization - cepiva - zdravilo proquad je indicirano za sočasno cepljenje proti ošpicam, mumpsu, rdečkam in noricam pri osebah, starih od 12 mesecev. proquad se lahko upravljajo posamezniki iz 9 mesecev starosti v posebnih okoliščinah (e. tako , da so skladni z nacionalnimi cepljenje urnike, izbruh situacijah, ali potovanje v regiji z visoko razširjenost ošpicam.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - cepiva - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 in 4. uporaba dengvaxia mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - v živo vidni nalezljive bursal bolezni virus (ibdv), sev 1052 - immunologicals za aves, domačo kokošjo, Živo virusna cepiva, ptic nalezljive bursal bolezni virus (bolezni gumboro) - chicken; embryonated chicken eggs - za aktivno imunizacijo 1-dan-stare pitovnih piščancev in embryonated pitovnih kokošja jajca za zmanjšanje kliničnih znakov bolezni in poškodb od bursa od fabricius, ki jih povzročajo zelo virulentni aviarne nalezljive bursal bolezni, okužbe z virusom.

Evropska unija - slovenščina - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - imunologija za aves - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - piščanec - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Evropska unija - slovenščina - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - cepiva - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

virbac 1ère avenue -